OMAPATRILAT & LISINOPRIL IN TREATMENT OF MODERATE HYPERTENSION

奥玛帕曲拉

• 批准号: 6303678
• 负责人: VITO M CAMPESE
• 金额: $ 3.56万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6303678
• 关键词: angiotensin /renin /aldosterone hypertension; angiotensin II; atrial natriuretic peptide; blood pressure; cardiovascular agents; cardiovascular disorder chemotherapy; cardiovascular pharmacology; clinical research; cyclic GMP; endothelin; human subject; human therapy evaluation; lisinopril; peptidyl dipeptidase A

The study will evaluate the effect of omapatrilat and lisinopril on blood pressure in subjects with salt-sensitive hypertension. a secondary objective is to compare the effects of the two drugs on urinary atrial natriuretic peptide (anp) on urinary cgmp and on plasma pra, anp, cgmp, angiotensin ii, angiotensin (1-7), endothelin and ace activity.

该研究将评估奥马帕特拉和赖诺普利对盐敏感性高血压患者血压的影响。第二个目的是比较两种药物对尿心房利钠肽（anp）对尿CGMP和血浆pra、anp、CGMP、血管紧张素ii、血管紧张素（1-7）、内皮素和ace活性的影响。